Sees FY25 LINZESS U.S. sales $800M-$850M. Sees FY25 adjusted EBITDA greater than $85M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on IRWD: Ironwood price target lowered to $8 from $10 at Craig-Hallum Ozempic, Xtandi among next 15 drugs selected for U.S. price talks Ironwood jumps after FDA rejects Zealand short bowel syndrome drug application Beam Therapeutics appoints Sravan Emany as CFO
